{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"84.5","value":"57.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"}],"units":"Participants"}],"title":"Predose Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"89.3","value":"80.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"}],"units":"Participants"}],"title":"Predose Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"82.9","value":"110"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"}],"units":"Participants"}],"title":"Predose Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"81.8","value":"115"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"}],"units":"Participants"}],"title":"Predose Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"68.9","value":"119"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"title":"Predose Cycle 6 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"315"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Necitumumab + Pemetrexed + Cisplatin\n\nNecitumumab: 800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V. infusion\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG000","title":"Necitumumab + Pemetrexed + Cisplatin"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants who were randomized to necitumumab and had evaluable PK data.","reportingStatus":"POSTED","timeFrame":"Predose Day 1 of Cycle 2,3,4,5 and 6 Prior to Necitumumab Infusion, Up to 23 Weeks","title":"Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab","type":"SECONDARY","unitOfMeasure":"micrograms/milliliter (ug/ml)"}